Enanta Pharmaceuticals (ENTA) Shares Sold by Gotham Asset Management LLC

Gotham Asset Management LLC cut its stake in shares of Enanta Pharmaceuticals (NASDAQ:ENTA) by 6.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 11,276 shares of the biotechnology company’s stock after selling 836 shares during the quarter. Gotham Asset Management LLC’s holdings in Enanta Pharmaceuticals were worth $662,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Teachers Advisors LLC increased its holdings in shares of Enanta Pharmaceuticals by 3.0% during the fourth quarter. Teachers Advisors LLC now owns 28,668 shares of the biotechnology company’s stock worth $1,682,000 after buying an additional 825 shares in the last quarter. Eqis Capital Management Inc. increased its holdings in shares of Enanta Pharmaceuticals by 3.3% during the fourth quarter. Eqis Capital Management Inc. now owns 31,099 shares of the biotechnology company’s stock worth $1,825,000 after buying an additional 997 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Enanta Pharmaceuticals by 30.0% during the third quarter. SG Americas Securities LLC now owns 5,662 shares of the biotechnology company’s stock worth $265,000 after buying an additional 1,308 shares in the last quarter. LS Investment Advisors LLC increased its holdings in shares of Enanta Pharmaceuticals by 56.8% during the fourth quarter. LS Investment Advisors LLC now owns 3,714 shares of the biotechnology company’s stock worth $218,000 after buying an additional 1,345 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Enanta Pharmaceuticals by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 139,428 shares of the biotechnology company’s stock worth $8,180,000 after buying an additional 1,798 shares in the last quarter. Institutional investors own 73.25% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of Enanta Pharmaceuticals stock opened at $80.91 on Monday. Enanta Pharmaceuticals has a twelve month low of $29.05 and a twelve month high of $95.91. The firm has a market capitalization of $1,550.32, a P/E ratio of 88.91 and a beta of 1.10.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.73. Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. The company had revenue of $38.11 million for the quarter, compared to analysts’ expectations of $27.26 million. analysts forecast that Enanta Pharmaceuticals will post 0.86 EPS for the current year.

In related news, Treasurer Paul J. Mellett sold 9,000 shares of the business’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $86.48, for a total value of $778,320.00. Following the sale, the treasurer now owns 96,458 shares of the company’s stock, valued at $8,341,687.84. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 10.56% of the company’s stock.

Several research analysts have recently issued reports on ENTA shares. Zacks Investment Research downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Royal Bank of Canada downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $54.00 price target for the company. in a report on Tuesday, January 2nd. TheStreet upgraded shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, December 13th. ValuEngine upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Finally, BidaskClub downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 10th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $57.40.

ILLEGAL ACTIVITY WARNING: “Enanta Pharmaceuticals (ENTA) Shares Sold by Gotham Asset Management LLC” was first reported by WKRB News and is the sole property of of WKRB News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.wkrb13.com/2018/04/02/enanta-pharmaceuticals-enta-shares-sold-by-gotham-asset-management-llc.html.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply